Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13667052 | 0.90 | ACMSD (0.36) | GAAMAPTNPC1KDM4EALDH1A1 | |
| SCHEMBL637142 | 0.90 | ACMSD (0.36) | GAAMAPTNPC1KDM4EALDH1A1 | |
| SCHEMBL16966536 | 0.90 | KCNQ3 (0.34) | — | |
| SCHEMBL13667492 | 0.87 | CNR2 (0.34) | MAPTKDM4EALDH1A1POLB | |
| SCHEMBL4401367 | 0.85 | CTSA (0.34) | MAPTNPC1POLBHPGD | |
| SCHEMBL637328 | 0.83 | HCRTR1 (0.37) | MAPTNPC1KDM4EPOLBHPGD | |
| SCHEMBL4399942 | 0.83 | PDE10A (0.35) | MAPTNPC1 | |
| SCHEMBL6032767 | 0.83 | HCRTR1 (0.37) | MAPTNPC1KDM4EPOLBHPGD | |
| SCHEMBL636539 | 0.83 | PDE10A (0.35) | MAPTNPC1 | |
| SCHEMBL636242 | 0.83 | ACMSD (0.37) | MAPTNPC1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | NFKB1 2232/4885NFKB2 1832/4885RELA 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.